Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome.
|
| Abstract |
Annexin A2 (ANXA2, an endothelial cell receptor for plasminogen and tissue plasminogen activator) has been identified as a new autoantigen in antiphospholipid syndrome (APS). The aim of the present study was to evaluate the presence of antibodies against the N-terminal domain of annexin A2 (ANXA2) in primary APS (PAPS). By using a synthetic peptide corresponding to the 31N-terminal amino acids of ANXA2 (ANXA2(N31)) as an antigen, we performed an enzyme-linked immunosorbent assay (ELISA) to measure anti-ANXA2(N31) IgG and IgM antibodies in the serum of PAPS patients (n=19), systemic lupus erythematosus (SLE) patients (n=50) and healthy blood donors (n=106). We did not find any statistically differences between the three groups in terms of IgG and IgM anti-ANXA2(N31) titres. Elevated IgG anti-ANXA2(N31) titres were not observed in the serum of PAPS or SLE patients who had previously tested positive for anti-ANXA2 antibodies. Thus, the ANXA2 N-terminal domain does not appear to be the target antigen for anti-ANXA2 antibodies in APS.
|
|---|---|
| Authors | V Salle, J C Mazière, A Brulé, J Schmidt, A Smail, P Duhaut, C Mazière, R Makdassi, G Choukroun, F Betsou, J P Ducroix |
| Journal | European journal of internal medicine (Eur J Intern Med) Vol. 23 Issue 7 Pg. 665-8 (Oct 2012) ISSN: 1879-0828 [Electronic] Netherlands |
| PMID | 22939813 (Publication Type: Journal Article) |
| Copyright | Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!